Human Papillomavirus Genotypes in the High Grade Preinvasive Cervical Lesions in Yaounde (Cameroon)

Zacharie Sando1,*, Tomas McKee2, Jean Claude Pache2, Herman Kemajou1, Olive Folem1, Laura Rubbia – Brandt2, Anderson Sama Doh1

1Department of Pathology, Gynaeo-obstetrics and Pediatric Hospital, Yaoundé, Cameroon
2Department of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland

*Corresponding author: sandozac@yahoo.fr

Received December 29, 2013; Revised August 19, 2013; Accepted August 21, 2013

Abstract The objectives of this study were to detect and determine the different genotypes of Human Papillomavirus (HPV) found in high-grade squamous preinvasive lesions of the uterine cervix of Cameroonian women. HPV genotyping was conducted on 37 endocervical secretions of women with high grade squamous intraepithelial lesions. HPV was found in 31 of the 37 women (83.8%); 9 different HPV genotypes were identified. The genotypes with high oncogenic potential were found in decreasing order of frequency as follows: 16, 18, 45, 33, 35 and 68. The frequency of strains found per patient ranged from 1 to 3. Genotypes 16 and 18 were single in 17 out of 31 patients. They were associated with other HPV genotypes in 4 out of 31 patients. In this study genotypes 16 and 18 are the most frequent genotypes encountered in high grade squamous preinvasive cervical lesions in Yaounde. This finding, if confirmed on a larger sample, portrays the potential effectiveness of HPV vaccines in the Cameroonian population as a preventive measure against cervical cancer. However, the position of genotype 45 is not negligible and should be confirmed on a large sample.

Keywords: human papillomavirus, high grade preinvasive lesion, cervix


1. Introduction

Cancer of the uterine cervix is today one of the biggest concerns of the medical community. It is the second most common gynecological cancer in women worldwide [1]. Each year, approximately 400,000 to 500,000 new cases of cervical cancer are diagnosed and are the cause of about 200,000 to 300,000 deaths [1]. About 80% of these cancers occur in developing countries, particularly in sub-Saharan Africa, in contrast to developed countries where frequency and mortality from this cancer is on the decrease [1].

In Yaounde Cameroon, it is the second most common cancer in women with a prevalence of 21.4% after breast cancer which accounts for 30.4% [2]. Invasive cancer is generally preceded by 10 to 15 years of precancerous lesions that are asymptomatic. These lesions represent the intermediate stage between normal cervical epithelium and invasive cervical cancer. Amongst them there are the low-grade lesions corresponding to cervical intraepithelial neoplasia of the first degree (CIN1) and high-grade lesions corresponding to cervical intraepithelial neoplasia of the second and third degrees (CIN2, CIN3). Between one to three years, the CIN1, CIN2 and CIN3 regress spontaneously in 57%, 43% and 32% of women respectively. Conversely, they progress to cancer in 1%, 1.5% and 12% for CIN1,CIN2 and CIN3 respectively [3]. There are many co-factors involved, but the Human Papillomavirus (HPV) is the etiological factor and is present in more than 99.7% of cervical cancers [4]. The genotypes of the virus can be classified according to their oncogenic potential (low or high). Persistent infection with highly oncogenic HPV is a necessity for progression to invasive cancer. There is an unequal distribution of HPV genotypes according to geographical area [5,6,7]. For example, there is a high prevalence of HPV type 16 in the Western world in contrast to Africa [1,5,6,7]. In Latin America and the Caribbean, multiples HPV are found in high grade lesions with 46, 5 % harboring HPV 16 and 8,9 % HPV 18 [8]. Multiple HPV genotypes have been also found in high grade lesions and cancer in America with HPV 16 the most frequent at all disease categories [9]. HPV vaccines currently proposed target only two highly oncogenic genotypes: 16, 18 and two genotypes of low oncogenicity: 6 and 11. Several studies of HPV genotype profile have been carried out in the world but very few in Cameroon. Most of these studies targeted the genotypes 16 and 18, and were done on the general female population, not including the fact that the attribution of HPV vaccine genotypes varies from a category of cervical disease to another [9]. In the absence of epidemiological data on the distribution of HPV genotypes in Cameroon,
namely in high-grade squamous intraepithelial lesions that are most at risk of becoming cancerous, we carried out a descriptive study of HPV genotypes in female patients with high-grade cervical lesions.

2. Materials and Methods

2.1. Site, Study Period and Setting

Recruitment of cases and data collection was done in the Department of pathology of the Yaoundé Gynaeco-Obstetrics and Pediatric Hospital (YGOPH) in Cameroon, from 1st January to 31st December 2009, among patients referred from the Gynecology Department for screening of precancerous lesions of the uterine cervix.

2.2. Criteria for Inclusion and Exclusion

Patients included in the study were aged at least 25 years from whom we obtained informed consent and whose cervical smears showed high grade precancerous lesions diagnosed on conventional smears (in Cameroon) or thin Prep (in Geneva) with histopathological confirmation from biopsy. Specimens from women undergoing surgery, radiotherapy or chemotherapy for gynecological cancer were excluded.

2.3. Samples Taken and Laboratory Methods

2.3.1. Collection of Cervical Smears

Patients received in the examination room were positioned in the gynecologic position on the examination table. After introduction of a non-lubricated, clean and single-use speculum (MediWare®, the endo-cervical secretions were collected using a cytobrush (Cervex-Brush® Rovers Medical Devices BV Lekstraat 10 5347 KV Oss, the Netherlands). After spreading the conventional pap smear on a glass slide, the head of the cytobrush with the specimen obtained by brushing the cervix was separated from its handle and then put into a vial containing a biological fixative (Cytix®) and labeled for identification of sampling. All the specimens were shipped at 20°C using dry ice, according to international standards within a period of three weeks.

2.3.2. Cytopathological Examination

Cytopathological examination of the samples from the patients was done after Papanicolaou stain procedure of the Department of Pathology of the YGOPH, Yaoundé Cameroon by a certified cytotechnician and certified cytopathologist. Thin Prep slides as well as the slides from biopsies were reviewed in the clinical pathology department of the University of Geneva, Switzerland by certified cytopathologists. The cytological abnormalities were classified according to Bethesda classification system (2001).

2.3.3. Detection of HPV

High grade cervical lesions diagnosed either in Thin Prep in Geneva or conventional Pap smear in Cameroon with histopathological confirmation from biopsies were enrolled in HPV detection. Detection and genotyping of HPV took place at the Department of Pathology, University Hospital of Geneva, under the supervision of Dr Tomas Mckee. An aliquot of the cervical sample was processed as described previously by Kuypers et al [10]. Briefly, the samples were precipitated and centrifuged, and the pellet dried and resuspended. HPV detection and typing was carried out using a polymerase chain reaction (PCR-), based reverse-line strip test for HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51–59, 66, 68, 73, 82, 83, and 84 as previously described [11]. B-globin was used as an internal control [11].

2.3.4. Ethical Considerations

The study was approved by both review board of Cameroon National Ethics Committee and the Geneva University Hospitals Ethics committee, Switzerland.

3. Results

Thirty nine women were enrolled in the study. Thirty seven specimens cytopathologically diagnosed as high grade squamous intraepithelial lesions (HGSIL) both in thin Prep and conventional smear, with histological confirmation of CIN2 or CIN3 were included in our study. There was a discrepancy in one case (ASCUS-H) with histopathological diagnosis of CIN1-2 and was excluded. Out of the 37 specimens retained, the HPV test was positive in 31 of the 37 women (83.8%). A total of 39 HPV isolates were identified amongst which we noted nine different HPV genotypes. The majority of these isolates (89.7%) were high risk (HR-HPV) including types 16 and 18 which accounted for 58.9% of the isolates and occupied respectively the first and second rows (Figure 1). Of the nine types of HPV identified, six genotypes were identified as HR-HPV and in descending order as follows: HPV16 (30.7%), HPV18 (28.2%), HPV45 (15.3%), HPV33 (7.6%), HPV35 (5.1%), and HPV 68 (2.5%); 3 genotypes were low risk (LR HPV) and in decreasing frequency as follows: HPV 11 (5.1%), HPV 53 (2.5%), and HPV 74 (2.5%).

Figure 1. Overview of the different genotypes encountered

Of the 31 women identified as carriers of high-oncogenic HPV, 28/31 (90.3%) were carriers of HR HPV and 3/31 (9.7%) were infected with LR HPV. Genotypes 16 and 18 that are used in the current HPV vaccines were single in 17out of 31 (54.8%) patients and were associated to other HPV types in 4out of 31 (12.9%) patients. The frequency of the HPV types found by
women ranged from 1 to 3. Of the 31 women with positive with HR-HPV test twenty six (83.9%) had one genotype, two (6.4%) 2 genotypes, and three (9.6%) 3 genotypes (Table 1).

<table>
<thead>
<tr>
<th>HPV</th>
<th>High grade lesion (H-SIL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
</tr>
<tr>
<td>One genotype</td>
<td>11</td>
</tr>
<tr>
<td>16</td>
<td>9</td>
</tr>
<tr>
<td>18</td>
<td>8</td>
</tr>
<tr>
<td>33</td>
<td>2</td>
</tr>
<tr>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>45</td>
<td>3</td>
</tr>
<tr>
<td>68</td>
<td>1</td>
</tr>
<tr>
<td>Two genotypes</td>
<td>16-45</td>
</tr>
<tr>
<td>18-45</td>
<td>1</td>
</tr>
<tr>
<td>Three genotypes</td>
<td>16 - 18 - 45</td>
</tr>
<tr>
<td>16 - 18 - 33</td>
<td>1</td>
</tr>
<tr>
<td>53 - 35 - 74</td>
<td>1</td>
</tr>
</tbody>
</table>

4. Discussion

In Cameroon some studies have been done on the awareness, knowledge, and belief on HPV, cancer and HPV vaccines, but no study on HPV detection in the high grade cervical lesions [12,13,14,15]. In our study, viral DNA was found in 83.8% cervical samples of the women. This result is similar to that found by Hyo Sung et al in Korea (89.4%) [16]. On the contrary, our finding is higher than that of Didelot-Rousseau et al in 2006 in Burkina Faso, Stevens M et al in Australia and Lindemann et al in Spain, who respectively had 66.1%, 68.35% and 65.4% in their studies [5,17,18].

This difference in prevalence in patients who had high-grade lesions could be explained by several factors, namely the viral genotyping procedure, and the detection technics used in these studies which require that the viral DNA be qualitatively and quantitatively satisfactory. Some technics requires a minimum of 10 to 100 copies of DNA for the sample to be positive. It is also possible that in some cases, the DNA could not be detected because of its poor quality. The sensitivity could attain 100% when the DNA is qualitatively adequate. Finally, there are cases where some factors as smoking and HIV infection are very important co-factors for progression to high-grade lesions than HPV alone [5,19].

We identified 9 types of HPV genotypes in 39 isolates of HPV. This result is much lower than that from Burkina Faso, where Didelot Rousseau et al identified 35 HPV genotypes [5]. This could be explained by our small sample size.

Other studies have shown that the distribution of HPV types was highly variable from one country to another [5,6,7,8,9]. The different HPV genotypes most frequently encountered in our study appeared to be similar to those found in high-grade precancerous lesions in the literature. Genotypes 16, 18, 45, 33, 35, 31 and 58 are present in most high-grade squamous intraepithelial lesions and 89% of cervical cancer [8,20,21].

Our results indicate that genotypes 16 and 18 are the most frequent genotypes (58.9%), and this is similar to findings from other studies Lindemann et al at the Spanish cohort found that the 16 and 18 HPV genotypes were responsible for 65.4% of high-grade lesions [18].

References


